Method of producing induced pluripotent stem cells using inhibitors of P53
Provided is a method of producing an iPS cell, comprising bringing (a) Oct3/4 or a nucleic acid that encodes the same, (b) Klf4 or a nucleic acid that encodes the same, and (c) Sox2 or a nucleic acid that encodes the same, as well as (d1) L-Myc or a nucleic acid that encodes the same and/or (d2) a functional inhibitor of p53, into contact with a somatic cell. It is preferable that (a) a nucleic acid that encodes Oct3/4, (b) a nucleic acid that encodes Klf4, (c) a nucleic acid that encodes Sox2, (d1) a nucleic acid that encodes L-Myc and (e) a nucleic acid that encodes Lin28 or Lin28b be inserted into an episomal vector having loxP sequences placed in the same orientation on the 5′ and 3′ sides of a vector constituent essential for the replication of the vector, that (d2) a nucleic acid that encodes an shRNA against p53 be inserted into a vector ensuring transient expression (plasmid vector and the like), and that all these nucleic acids be transferred to a somatic cell.
1. A method of producing iPS cells in vitro, comprising introducing
(a) an episomal vector comprising a nucleic acid sequence that encodes Oct3/4,
(b) an episomal vector comprising a nucleic acid sequence that encodes Klf4,
(c) an episomal vector comprising a nucleic acid sequence that encodes Sox2,
(d) an episomal vector comprising a nucleic acid sequence that encodes
(i) L-Myc, and
(ii) Lin28 or Lin28b joined polycistronically in the orientation of 5′-3′, and
(e) a functional inhibitor of p53 selected from the group consisting of
(i) an siRNA against p53,
(ii) an shRNA against p53, and
(iii) DNA encoding an siRNA or shRNA against p53, wherein the DNA can be in the form of an episomal vector,
into a somatic cell such that iPS cells are produced,
wherein the episomal vectors of (a) to (e) can be the same or different.
2. The method according to claim 1 , wherein the somatic cell is a human cell.
3. The method according to claim 2 , comprising culturing the human cell in the absence of an ingredient from a non-human animal after introducing (a), (b), (c), (d), and (e) into the somatic cell.
4. The method of claim 1 , wherein b) and c) the same.
5. The method of claim 4 , wherein a) and e) are in the same.
6. The method of claim 1 , wherein a) and e) are in the same.